Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBT Margin (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of EBT Margin data on record, last reported at 6039.76% in Q3 2025.

  • For Q3 2025, EBT Margin fell 606154.0% year-over-year to 6039.76%; the TTM value through Sep 2025 reached 343.61%, down 8572.0%, while the annual FY2024 figure was 169.74%, 2056.0% down from the prior year.
  • EBT Margin reached 6039.76% in Q3 2025 per SGMO's latest filing, down from 109.03% in the prior quarter.
  • Across five years, EBT Margin topped out at 21.78% in Q3 2024 and bottomed at 10185.24% in Q1 2024.
  • Average EBT Margin over 5 years is 2008.82%, with a median of 200.77% recorded in 2022.
  • Peak YoY movement for EBT Margin: plummeted -1019874bps in 2024, then surged 1001850bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 166.66% in 2021, then fell by -14bps to 189.92% in 2022, then tumbled by -1462bps to 2966.06% in 2023, then soared by 88bps to 366.51% in 2024, then plummeted by -1548bps to 6039.76% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 6039.76% in Q3 2025, 109.03% in Q2 2025, and 473.48% in Q1 2025.